Provides a list of topics to be covered the first day of the meeting.

Provides a list of topics to be covered on Day 3 of June BAP meeting

Provides clinical and cost-effectiveness conclusions for P&T committee decisions based on evaluation and review of utilization trends.

Provides clinical and cost-effectiveness conclusions for formulary placement of agents based on evaluation by P&T committee and utilization review

Provides additional clarification and guidance on P&T decisions from May 2025 committee meeting

Provides clinical and cost-effectiveness conclusions for P&T committee decisions in August 2025 based on evaluation and review of utilization trends.

Provides clinical and cost-effectiveness conclusions for P&T committee decisions based on evaluation and review of utilization trends from the February 2026 meeting

Provides recommendations of the P&T Committee on formulary inclusion of new drugs, drug class reviews, conclusions from utilization management, and final votes

Contains summary of proceedings and recommendations for formulary inclusion and drug class reviews evaluated by P&T Committee in February 2026

Contains clarification and instructions for therapeutic substitution of selected medications and explains P&T authorities for therapeutic substitution

Cumulative P&T minutes for February, May, August and November 2025 P&T meetings reflecting formulary recommendations and final decisions

Contains the summary of proceedings, recommendations and actions from November P&T Committee Meeting

Summarizes the proceedings and recommendations of the P&T committee concerning formulary inclusions and drug class reviews evaluated by P&T committee in November 2025

Clarifies and outlines the process of therapeutic substitution of selected agents and establishes the authority of the P&T Committee in this endeavor

UF BAP EXSUM and Meeting Minutes December 18 2024